MK-2866 vs Semaglutide for weight loss
Short answer: For weight loss, more users report improvement with MK-2866 — 89% of 80 reports, versus 84% of 129 for Semaglutide.
MK-2866 has 0 meta-analyses and 0 randomized trials on PubMed; Semaglutide has 421 and 307.
Based on 612 reports about MK-2866 and 314 about Semaglutide. Not medical advice.
| MK-2866 SARM | Semaglutide Medication | |
|---|---|---|
| User score | 33 | 64 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 39% | 64% |
| Reports | 612 | 314 |
| Research | DResearch: None | AResearch: Strong |
| Meta-analyses / RCTs | 0 / 0 | 421 / 307 |
| Mainly used for | ||
| Weight loss % reporting improvement | 89% (80) | 84% (129) |
| Appetite % reporting improvement | 62% (8) | 83% (64) |
| Focus % reporting improvement | 71% (7) | 60% (5) |
| Energy % reporting improvement | 54% (37) | 39% (23) |
| Sleep % reporting improvement | 20% (20) | 50% (4) |
| Anxiety % reporting improvement | 33% (9) | — |
| Mood % reporting improvement | 63% (49) | 27% (11) |
| Performance % reporting improvement | 88% (192) | 83% (6) |
| Recovery % reporting improvement | 97% (60) | 100% (2) |
| Pain & inflammation % reporting improvement | 70% (27) | 80% (5) |
| Digestion % reporting improvement | — | 43% (7) |
| Libido % reporting improvement | 31% (45) | 0% (3) |
| Hormones % reporting improvement | 4% (82) | 100% (2) |
| Blood sugar % reporting improvement | — | 88% (8) |
| Heart & lipids % reporting improvement | 0% (8) | 100% (3) |
| Skin & hair % reporting improvement | 33% (6) | 33% (3) |
| Common side effects | suppression, fatigue, insomnia, headache | nausea, fatigue, stomach issues, constipation |
| Typical dose reported | Not listed | 2.4 mg / once weekly |
MK-2866Full MK-2866 profile →
What a user said
“I've taken LDG-4033 and Ostarine from Ceretropic and noticed slight psychoactive effects from both, immediately (within 30 minutes after dosing).”
SemaglutideFull Semaglutide profile →
Latest review conclusion
This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
Pharmacol Res, 2021 ↗What a user said
“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate